Valuation: Evofem Biosciences, Inc.

Market Cap 1.19M 1.04M 962K 892K 1.69M 113M 1.72M 11.53M 4.49M 55.87M 4.48M 4.38M 193M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.61M 48.66M 44.85M 41.57M 78.91M 5.28B 80.18M 538M 209M 2.6B 209M 204M 9B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+6.67%
1 week+20.00%
Current month+20.00%
1 month+17.07%
3 months+6.67%
6 months+6.67%
Current year+1.05%
1 week 0.01
Extreme 0.0077
0.01
1 month 0.01
Extreme 0.007
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.82
5 years 0
Extreme 0.0008
1,950
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 2017-12-31
Director of Finance/CFO 49 2023-04-12
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
24-01-11Sell

Chief Financial Officer

104 0.0010%
23-12-20Sell

Director

10 0.0001%
23-04-12Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+6.67%+20.00%-3.03%-98.77% 1.19M
+3.00%+3.00%+59.85%+173.28% 1,070B
+3.19%+5.12%+71.94%+67.65% 624B
+0.18%+1.20%+35.72%+87.94% 450B
+2.14%-2.07%+27.62%+22.57% 328B
+1.87%+1.87%+40.58%+42.08% 292B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.30%+1.36%+25.29%+67.87% 198B
+4.51%+6.76%+20.66%+81.23% 161B
Average +2.54%+1.75%+28.28%+45.42% 362.44B
Weighted average by Cap. +2.25%+0.70%+43.37%+88.01%

Financials

2024 2025
Net sales 19.36M 16.94M 15.62M 14.47M 27.48M 1.84B 27.92M 187M 72.82M 907M 72.69M 71.12M 3.13B 20.18M 17.66M 16.28M 15.09M 28.64M 1.92B 29.1M 195M 75.9M 945M 75.77M 74.13M 3.27B
Net income -8.86M -7.75M -7.15M -6.62M -12.57M -841M -12.78M -85.68M -33.32M -415M -33.26M -32.54M -1.43B 391K 342K 315K 292K 555K 37.11M 564K 3.78M 1.47M 18.31M 1.47M 1.44M 63.3M
Net Debt 45.84M 40.11M 36.97M 34.27M 65.05M 4.35B 66.1M 443M 172M 2.15B 172M 168M 7.42B 54.42M 47.62M 43.89M 40.68M 77.22M 5.16B 78.46M 526M 205M 2.55B 204M 200M 8.81B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
26-07-07 US$0.009600 +6.67% 219,513
26-07-06 US$0.009000 +12.50% 131,972
26-07-02 US$0.008000 -9.09% 614,709
26-07-01 US$0.008800 +10.41% 2,247,181
26-06-30 US$0.007970 -3.80% 10,231

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock